Sepsis Risk Articles & Analysis
9 news found
The study, “Assessment of a cellular host response test to risk-stratify suspected COVID-19 patients in the Emergency Department setting,” demonstrated that the IntelliSep test has the potential to rapidly risk-stratify patients independent of pathogen, an important finding as risk stratification may improve resource allocation in ...
Cytovale, a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, has received additional funding from Biomedical Research and Development Authority (BARDA) to help advance the company’s 10-minute IntelliSep sepsis risk stratification test towards commercial ...
Each year, more than 1.4 million patients with false-positive blood culture results are put at risk for sepsis misdiagnosis which can have serious impacts including unnecessary and prolonged antibiotic therapy, extended hospital stays, increased risk of hospital-acquired infections and increased morbidity and mortality. The problem of ...
Conversely, treating patients for sepsis when they do not have it taxes the health system, risks overuse of antibiotics, and may delay care for their true illness. ...
CARB-X is awarding Accelerate Diagnostics, a Tucson, Arizona, USA, biotech company, up to US$578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. Accelerate would be eligible for up to $2.1 million in additional funds from CARB-X if the project meets certain milestones, subject to available funds. ...
The study’s primary endpoint is a comparison to sepsis as adjudicated by an independent panel of physicians, the gold standard for sepsis determination. ...
Conversely, treating patients for sepsis when they do not have it taxes the health system, risks overuse of antibiotics, and may delay care for their true illness. ...
Fonseca will oversee Inflammatix’s molecular assay development and engineering teams as the company advances its rapid tests for acute infections, sepsis, and COVID-19 risk stratification. “João is an exceptional scientist and executive with a successful track record for building breakthrough diagnostics products, particularly at ...
Delivering on this strategy, Abionic is about to launch a multinational sepsis impact study of it’s Pancreatic Stone Protein (PSP) test for sepsis risk assessment and management, the only device worldwide that provides results showing an indication of sepsis within 5 minutes. ...